BioLineRx (BLRX) EBITDA Margin (2024 - 2025)
BioLineRx's (BLRX) quarterly EBITDA Margin came in at 1745.36% in Q4 2025, down 170769.0% year-on-year from N/an in Q4 2024, and down 237.68% quarter-over-quarter from 516.86% in Q3 2025.
BioLineRx (BLRX) EBITDA Margin (2024 - 2025) Analysis & Trends
BioLineRx's EBITDA Margin history runs 2 years deep, the most recent figure standing at 1745.36% for Q4 2025.
- On a quarterly basis, EBITDA Margin fell 170769.0% year-over-year to 1745.36% in Q4 2025; TTM through Dec 2025 was 871.78%, a 80126.0% decrease from a year earlier, with the FY2025 full-year figure at 871.78%, down 80126.0% from the prior year.
- EBITDA Margin slipped to 1745.36% in Q4 2025 per BLRX's latest filing, from 516.86% in the prior quarter.
- Across five years, EBITDA Margin topped out at 37.67% in Q4 2024 and bottomed at 1745.36% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 | -1,745.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,745.36% |
| Sep 30, 2025 | -516.86% |
| Jun 30, 2025 | -757.57% |
| Mar 31, 2025 | -937.65% |
| Dec 31, 2024 | -37.67% |
| Sep 30, 2024 | -108.98% |
| Jun 30, 2024 | -107.05% |
| Mar 31, 2024 | -70.34% |